Pharmabiz

SOFIE Biosciences doses first patient dosed in phase 3 trials of [18F]FAPI-74, a fluorine-18 labelled radiopharmaceutical targeting FAP for patients with GI cancers

SOFIE Biosciences doses first patient dosed in phase 3 trials of [18F]FAPI-74, a fluorine-18 labelled radiopharmaceutical targeting FAP for patients with GI cancers: Dulles, Virgi ...
Pharmabiz

China NMPA accepts and grants priority review status to Hutchmed’s NDA for fanregratinib in second-line intrahepatic cholangiocarcinoma

China NMPA accepts and grants priority review status to Hutchmed’s NDA for fanregratinib in second-line intrahepatic cholangiocarcinoma: Hong Kong, Shanghai Wednesday, December ...
Pharmabiz

US FDA grants 510(k) clearance to StimLabs’ Theracor, a first human umbilical cord-derived medical device sheet

US FDA grants 510(k) clearance to StimLabs’ Theracor, a first human umbilical cord-derived medical device sheet: Roswell, Georgia Wednesday, December 31, 2025, 13:00 Hrs [IST] S ...
Pharmabiz

India in 2026 will work to advance integrated, tech-enabled healthcare with focus on mental wellbeing

Nandita Vijayasimha, Bengaluru Wednesday, December 31, 2025, 09:00 Hrs [IST] ...
Pharmabiz

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...
Pharmabiz

Establishment Labs Holdings submits Motiva implants to US FDA for approval in primary and revision breast reconstruction

Establishment Labs Holdings submits Motiva implants to US FDA for approval in primary and revision breast reconstruction: Costa Rica Wednesday, December 31, 2025, 16:00 Hrs [IST] ...
Pharmabiz

Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis

Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis: Salt Lake City Wednesday, December 31, 2025, 11:00 Hrs ...
Pharmabiz

Enveric Biosciences receives US patent entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives”

Enveric Biosciences, a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, announced the issuance of US Patent No. 12, ...
Pharmabiz

Johnson & Johnson completes acquisition of clinical-stage biotechnology company, Halda Therapeutics

Johnson & Johnson completes acquisition of clinical-stage biotechnology company, Halda Therapeutics: New Brunswick, New Jersey Wednesday, December 31, 2025, 12:00 Hrs [IST] Johnso ...
Pharmabiz

WORK Medical’s subsidiary Hunan Saitumofei receives manufacturing approval for its Class II medical devices

WORK Medical’s subsidiary Hunan Saitumofei receives manufacturing approval for its Class II medical devices: Hangzhou, China Wednesday, December 31, 2025, 15:00 Hrs [IST] WORK M ...
Pharmabiz

Almost 85% of overcharged amount claimed by NPPA yet to be recovered

Almost 85% of overcharged amount claimed by NPPA yet to be recovered: Gireesh Babu, New Delhi Wednesday, December 31, 2025, ...
Pharmabiz

Circadian rhythm regulation in delayed sleep phase syndrome

Delayed sleep phase syndrome (DSPS) is a most prevalent circadian rhythm sleep disorder and is marked by a delay in the timing of sleep episode compared to desired or necessary sleeping and wakeup ...